Kalray Wins Flash Memory Summit Award for the Second Year in a Row
10.8.2023 17:48:00 EEST | Business Wire | Press release
Kalray (Euronext Growth Paris: ALKAL), a leading provider of hardware and software technologies and solutions for the high-performance, data-centric computing and storage markets, has been recognized as the leader of the DPU category in the 17th Annual Flash Memory Summit Awards competition.
Flash Memory Summit (FMS) is the world’s largest international comprehensive memory and storage showcase, hosted at the Santa Clara Convention Center, California, USA. The new Kalray K220-LP Storage Acceleration Card, powered by Kalray's 3rd generation DPU processor, won the FMS Award in the DPU category. This Flash Memory Summit Award symbolizes the industry's acknowledgment of the innovation and business value that Kalray solutions bring to the market.
KALRAY UNVEILS ITS NEW K220-LP™ SMART STORAGE ACCELERATOR
Kalray’s K220-LP™ Smart Storage Accelerator (SSA) was introduced at FMS this year, bringing storage offload to the next level. By offloading intensive storage data services from the main CPU, the SSA releases all the potential of NVMe SSDs in any server with local NVMe devices. The main CPU is freed to perform billable tasks while all storage-related tasks are offloaded to the Kalray K220-LP™ Smart Storage Accelerator.
“Customers have a need to maximize their server investments by pursuing greater optimization and performance. This can be achieved by offloading storage data services to specialized processors for maximum ROI of the server infrastructure,” said Jay Kramer, chairman of the awards program and president of Network Storage Advisors Inc. “We are proud to recognize Kalray’s Smart Storage Accelerators for their ability to efficiently store both data and metadata on storage class memory (SCM) while offloading storage data services and applications from the main CPU. This solution enables customers to realize the full potential of local NVMe SSDs deployed in any industry-standard server.”
KALRAY DEMONSTRATES THAT QLC MEMORY ADOPTION BENEFITS DATA CENTERS
As a powerful use case, Kalray demonstrated how its solution allows a new generation of SSDs, called QLC SSDs, to be adopted into data centers without requiring any changes to the data center operating system, file system, or applications. Kalray DPUs have accelerators, fast coherent memory, and flexible programmability, which makes them ideal for storage management functions such as managing new QLC technology. Thanks to Kalray’s solution, data centers can take full advantage of the price, capacity, and performance benefits of QLC flash devices. The result is a data center that realizes the benefits of QLC without performance and durability penalties and without the need to modify existing software.
“QLC SSDs present great economic advantages by delivering greater capacity and density. But compared to other SSD types, QLC technology has challenges to overcome, including lower endurance, higher latency, and reduced performance under heavy workloads,” added Jay Kramer. “We are proud to recognize Kalray’s Smart Storage Accelerators for their highly effective performance in enabling a simple deployment on industry-standard servers. This solution allows customers to achieve cost and capacity benefits of QLC devices transparently, with no hardware architectural changes and no software stack changes.”
ACKNOWLEDGEMENT OF THE SOLUTION’S INNOVATION
“It is a great honor to win a Flash Memory Summit award for the second year in a row,” said Éric Baissus, chief executive officer of Kalray. “This award represents strong recognition of the value of our solutions. Customers who integrate our new K220-LP™ SSA into their servers can accelerate the transition from traditional storage architectures relying on SAS (Serial Attached SCSI) to high-performance, power-efficient NVMe-based solutions.”
The K220-LP™ solution includes Kalray’s AccessCore® Storage (ACS) software SDK. Thanks to ACS SDK, the K220-LP™ SSA is fully programmable, enabling offload of custom storage or computational application processing, thus removing the usual bottlenecks of traditional architectures. The Kalray solution enables data centers to leapfrog outdated technologies that are unable to sustain the storage requirements of demanding workloads and embrace the benefits of modern, scalable, and flexible data solutions with minimal effort.
This is the second consecutive award Kalray has received from Flash Memory Summit, maintaining momentum in innovation following last year’s award for most innovative technology with Flashbox™.
ABOUT KALRAY
Kalray (Euronext Growth Paris – FR0010722819 – ALKAL) is a leading provider of hardware and software technologies and solutions for high-performance, data-centric computing markets, from cloud to edge. Kalray provides a full range of products to enable smarter, more efficient, and energy-wise data-intensive applications and infrastructures.
Kalray’s offerings include unique patented DPU (Data Processing Unit) processors and acceleration cards, as well as leading-edge software-defined storage and data management solutions. Separated or in combination, Kalray’s high-performance solutions allow its customers to improve the efficiency of data centers and to design the best solutions in fast-growing sectors such as AI, media & entertainment, life science, scientific research, edge computing, automotive and others.
Founded in 2008 as a spin-off of the well-known French CEA research lab, with corporate and financial investors such as Alliance Venture (Renault-Nissan-Mitsubishi), NXP Semiconductors or Bpifrance, Kalray is dedicated through technology, expertise, and passion to offer more: more for a smart world, more for the planet, more for customers and developers. Visit us at www.kalrayinc.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230809063602/en/
Contact information
INVESTORS
Eric BAISSUS
contactinvestisseurs@kalrayinc.com
Tel. 04 76 18 90 71
ACTUS finance & communication
Anne-Pauline PETUREAUX
kalray@actus.fr
Tel. 01 53 67 36 72
PRESS
Diana EADINGTON
communication@kalrayinc.com
Tel. +44 7939 877 880
ACTUS finance & communication
Serena BONI
sboni@actus.fr
Tel. 04 72 18 04 92
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom